Press release archive 2011

Tuesday, 20 December 2011
AstraZeneca updates on olaparib and TC-5214 development programmes AstraZeneca today announced that its investigational compound olaparib will not progress into Phase III development for the maintenance treatment of serous ovarian cancer. In addition, AstraZeneca announced that the second RENAISSANCE Phase III study of TC-5214 for patients with major depressive disorder did not meet its primary end point. As a result, AstraZeneca will take pre-tax impairment charges totalling $381.5 million to R&D expense in the fourth quarter of 2011. The company confirms its expectation for full year Core EPS in the range of $7.20 to $7.40, but with the inclusion of these intangible impairments, Core EPS is likely to be in the lower half of this range.
Thursday, 15 December 2011
G-BA issues positive final medical benefit assessment for BRILIQUE in Germany AstraZeneca today announced that the German assessment body, the Federal Joint Committee (G-BA), has issued its final decision regarding the medical benefit of BRILIQUE (ticagrelor).  This positive decision is in line with the preliminary assessment published by the Institute for Quality and Efficiency in Healthcare (IQWiG) in October, with the addition of a new ST-Elevation Myocardial Infarction/Percutaneous Coronary Intervention (STEMI/PCI) sub-group for patients over 75 years or patients with prior stroke or transient ischemic attack (TIA).
Thursday, 8 December 2011
AstraZeneca to acquire generics company to broaden patient access to medicines in China AstraZeneca today announced it has entered into an agreement to acquire Guangdong BeiKang Pharmaceutical Company Ltd, a privately-owned generics manufacturing company, based in Conghua City, Guangdong province, China. The deal will give AstraZeneca access to a portfolio of injectable medicines used to treat infections which AstraZeneca will make available to patients in China.
Wednesday, 7 December 2011
AstraZeneca to streamline US sales organisation AstraZeneca announced today that it will reduce its US sales force by approximately 1,150 leadership positions and sales representatives as part of the company’s ongoing strategy to operate its business more efficiently to best serve patients in the US.
Monday, 5 December 2011
Groundbreaking scientific collaboration gives UK academia access to compounds to advance medical research A wide range of compounds will be made available free of charge to UK medical researchers next year, following a landmark agreement between the Medical Research Council (MRC) and AstraZeneca. In a new type of collaboration, academia will be granted access to 22 compounds, developed by AstraZeneca. Through MRC funding, UK academia will conduct studies to better understand what drives a range of diseases with a view to exploring new treatment opportunities.
Tuesday, 29 November 2011
KOMBOGLYZE™ receives marketing authorisation in the European Union for adult patients with Type 2 diabetes AstraZeneca and Bristol-Myers Squibb Company announced today that the European Commission has granted marketing authorisation for KOMBOGLYZE™ (saxagliptin and metformin HCl immediate-release fixed dose combination) that will cover the 27 Member States of the European Union.
Monday, 28 November 2011
AstraZeneca commits an additional $100 million to venture capital arm MedImmune Ventures AstraZeneca today announced that it has committed an additional $100 million to its venture capital arm, MedImmune Ventures, increasing the total capital under management to $400 million. MedImmune Ventures is an evergreen venture capital fund that focuses on equity investments in private companies in the areas of biopharmaceuticals, medical and healthcare technology.
Friday, 18 November 2011
CAPRELSA™ (vandetanib) receives positive CHMP opinion in the European Union for treating advanced medullary thyroid cancer AstraZeneca today announced that the Marketing Authorisation Application for CAPRELSA (vandetanib) received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) for the treatment of aggressive and symptomatic medullary thyroid cancer (MTC) in patients with unresectable locally advanced or metastatic disease. The proposed indication also states that for patients in whom Rearranged during Transfection (RET) mutation is not known or is negative, a possible lower benefit should be taken into account before individual treatment decisions
Tuesday, 15 November 2011
SATURN demonstrated effect of intensive statin treatment on reducing atherosclerosis Data presented at this year’s AHA reinforces the established efficacy profile of CRESTOR (rosuvastatin)
Tuesday, 8 November 2011
AstraZeneca and Targacept announce first top-line Phase III results for TC-5214 as an adjunct treatment in patients with major depressive disorder AstraZeneca and Targacept, Inc. today announced top-line results from the first of four RENAISSANCE Phase III studies investigating the efficacy and tolerability of TC-5214 as an adjunct therapy to an antidepressant in patients with major depressive disorder (MDD) who do not respond adequately to initial antidepressant treatment. The study did not meet its primary endpoint of change on the Montgomery-Asberg Depression Rating Scale (MADRS) after eight weeks of treatment with TC-5214 as compared to placebo.